Kural-Seyahi E, Fresko I, Seyahi N, et al. The long-term mortality and morbidity of Behcet's syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore). 2003;82:60-76.
International Study Group for Behcet's Disease. Criteria for diagnosis of Behcet's disease. Lancet. 1990;335:1078-1080.
1. Yazici H, Fresko I, Yurdakul S. Behcet's syndrome: disease manifestations, management, and advances in treatment. Nat Clin Pract Rheumatol. 2007 Mar;3(3):148-55.
2. Behcet H. Uber rezidivierende aphthöse, durch ein Virus Verursachte Geschwure am Mund, am Auge und an den Genitalien. Dermatol Wschr [in German]. 1937;105:1152-1157.
3. Sakane T, Takeno M, Suzuki N, et al. Behcet's syndrome. N Engl J Med. 1999;34:1284-1291.
4. Kural-Seyahi E, Fresko I, Seyahi N, et al. The long-term mortality and morbidity of Behcet's syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore). 2003;82:60-76.
5. Yurdakul S, Gunaydin I, Tuzun Y, et al. The prevalence of Behcet's syndrome in a rural area in northern Turkey. J Rheumatol. 1988;15:820-822.
6. Yurdakul S, Tuzuner N, Yurdakul I, et al. Gastrointestinal involvement in Behcet's syndrome: a controlled study. Ann Rheum Dis. 1996;55:208-210.
7. Yazici Y, Adler NM. Clinical manifestations and ethnic background of patients with Behcet's syndrome in a US cohort. Arthritis Rheum. 2007;56(suppl):S502.
8. Gul A, Hajeer AH, Worthington J, et al. Linkage mapping of a novel susceptibility locus for Behcet's syndrome to chromosome 6p22-23. Arthritis Rheum. 2001;44:2693-2696.
9. Direskeneli H. Autoimmunity vs autoinflammation in Behcet's syndrome: do we oversimplify a complex disorder? Rheumatology (Oxford). 2006;45:1461-1465.
10. Tunc R, Keyman E, Melikoglu M, et al. Target organ associations in Turkish patients with Behcet's syndrome: a cross sectional study by exploratory factor analysis. J Rheumatol. 2002;29:2393-2396.
11. Fresko I, Soy M, Hamuryudan V, et al. Genetic anticipation in Behcet's syndrome. Ann Rheum Dis. 1998;57:45-48.
12. Hamuryudan V, Er T, Seyahi E, et al. Pulmonary artery aneurysms in Behcet's syndrome. Am J Med. 2004;117:867-870.
13. Fresko I, Ugurlu S, Ozbakir F, et al. Anti-Saccharomyces cerevisiae antibodies (ASCA) in Behcet's syndrome. Clin Exp Rheumatol. 2005;23(suppl 38):S67-S70.
14. International Study Group for Behcet's Disease. Criteria for diagnosis of Behcet's disease. Lancet. 1990;335:1078-1080.
15. Fresko I, Yazici H. Treatment strategies for Behcet's disease. Expert Opin Pharmacother. 2008;9:3211-3219.
16. Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet's syndrome. Ann Rheum Dis. 2018 Jun;77(6):808-818.
17. Hamuryudan V, Hatemi G, Tascilar K, et al. Colchicine in Behcet syndrome: a longterm survey of patients in a controlled trial. J Rheumatol. 2014;41:735-738.
18. Hatemi G, Melikoglu M, Tunc R, et al. Apremilast for Behçet's syndrome: a phase 2, placebo-controlled study. N Engl J Med. 2015;372:1510-1518.
使用此内容应接受我们的免责声明。
BMJ临床实践的持续改进离不开您的帮助和反馈。如果您发现任何功能问题和内容错误,或您对BMJ临床实践有任何疑问或建议,请您扫描右侧二维码并根据页面指导填写您的反馈和联系信息*。一旦您的建议在我们核实后被采纳,您将会收到一份小礼品。
如果您有紧急问题需要我们帮助,请您联系我们。
邮箱:bmjchina.support@bmj.com
电话:+86 10 64100686-612
*您的联系信息仅会用于我们与您确认反馈信息和礼品事宜。
BMJ临床实践官方反馈平台